The adoption of mental health drugs on state AIDS drug assistance program formularies
- PMID: 21493949
- PMCID: PMC3093265
- DOI: 10.2105/AJPH.2010.300100
The adoption of mental health drugs on state AIDS drug assistance program formularies
Abstract
Objectives: We sought state-level factors associated with the adoption of medications to treat mental health conditions on state formularies for the AIDS Drug Assistance Program.
Methods: We interviewed 22 state and national program experts and identified 7 state-level factors: case burden, federal dollar-per-case Ryan White allocation size, political orientation, state wealth, passage of a mental health parity law, number of psychiatrists per population, and size of mental health budget. We then used survival analysis to test whether the factors were associated with faster adoption of psychotropic drugs from 1997 to 2008.
Results: The relative size of a state's federal Ryan White HIV/AIDS Program allocation, the state's political orientation, and its concentration of psychiatrists were significantly associated with time-to-adoption of psychotropic drugs on state AIDS Drug Assistance Program formularies.
Conclusions: Substantial heterogeneity exists across states in formulary adoption of drugs to treat mental illness. Understanding what factors contribute to variation in adoption is vital given the importance of treating mental health conditions as a component of comprehensive HIV care.
Similar articles
-
Managing psychotropic drug costs: will formularies work?Health Aff (Millwood). 2003 Sep-Oct;22(5):84-96. doi: 10.1377/hlthaff.22.5.84. Health Aff (Millwood). 2003. PMID: 14515884
-
Choosing drug of choice from restrictive formulary.J Clin Psychopharmacol. 1997 Jun;17(3):145-8. doi: 10.1097/00004714-199706000-00001. J Clin Psychopharmacol. 1997. PMID: 9169956 No abstract available.
-
Associations between food insecurity and psychotropic medication use among women living with HIV in the United States.Epidemiol Psychiatr Sci. 2020 Apr 6;29:e113. doi: 10.1017/S2045796020000232. Epidemiol Psychiatr Sci. 2020. PMID: 32248873 Free PMC article.
-
Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome.Psychiatr Clin North Am. 2002 Mar;25(1):149-75. doi: 10.1016/s0193-953x(03)00056-x. Psychiatr Clin North Am. 2002. PMID: 11912937 Review.
-
Mental health policy and psychotropic drugs.Milbank Q. 2005;83(2):271-98. doi: 10.1111/j.1468-0009.2005.00347.x. Milbank Q. 2005. PMID: 15960772 Free PMC article. Review.
Cited by
-
Integrating substance abuse treatment into HIV care: missed opportunities in the AIDS Drug Assistance Program.J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):421-9. doi: 10.1097/QAI.0b013e31827ee56c. J Acquir Immune Defic Syndr. 2013. PMID: 23202815 Free PMC article.
-
Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009.PLoS One. 2013 Nov 18;8(11):e78952. doi: 10.1371/journal.pone.0078952. eCollection 2013. PLoS One. 2013. PMID: 24260137 Free PMC article. Clinical Trial.
References
-
- Committee on Public Financing and Delivery of HIV Care, Board on Health Promotion and Disease Prevention Public Financing and Delivery of HIV/AIDS Care: Securing the Legacy of Ryan White. Washington, DC: National Academies Press; 2005
-
- Grassi L. Risk of HIV infection in psychiatrically ill patients. AIDS Care. 1996;8(1):103–116 - PubMed
-
- Carey MP, Carey KB, Kalichman SC. Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illness. Clin Psychol Rev. 1997;17(3):271–291 - PubMed
-
- Sullivan G, Koegel P, Kanouse DE, et al. HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care. Psychiatr Serv. 1999;50(5):648–652 - PubMed
-
- Weiser SD, Wolfe WR, Bangsberg DR. The HIV epidemic among individuals with mental illness in the United States. Curr HIV/AIDS Rep. 2004;1(4):186–192 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical